veracyte.那South San Francisco, Calif, and Decipher Biosciences, San Diego, Calif, a commercial-stage precision oncology company focused on urologic cancers, have entered into a definitive agreement through which Veracyte will acquire Decipher, further solidifying Veracyte’s global leadership in the genomic cancer diagnostics market while accelerating revenue growth.

“By combining Decipher Biosciences’ leadership in urologic cancers with our comprehensive genomic testing menu, Veracyte will be able to serve patients across the clinical care continuum in 7 of the 10 most prevalent cancers in the United States with highly differentiated and clinically impactful tests, significantly accelerating revenue growth and driving shareholder value,” says Bonnie Anderson, Veracyte’s chairman and chief executive officer. “Further, with our best-in-class nCounter diagnostics platform, we are well-positioned to deliver comprehensive genomic cancer testing to physicians and their patients worldwide. I am also delighted that Dr Tina Nova, PhD, Decipher’s president and CEO, and a veteran diagnostics industry leader, will join Veracyte as general manager, urologic cancers, and that Decipher’s talented employees will also join our team.”



破译前列腺活检和后自由基前列腺切除术(RP)测试包括在NCCN指南中,破译前列腺RP检测是NCCN在NCCN指南中唯一用于局部前列腺癌患者的基因组分子诊断试验。他们也广泛地被医疗保险和私人付款人偿还,并包括在实践 - 不断变化的临床试验中,随着泌尿外科群落的采用日益增加。此外,该公司的破译膀胱试验预计将在2021年在商业上发动,其肾癌试验正在开发中。破译网格,一个大型良好的泌尿表层癌数据库,推动了公司的生物制药伙伴关系和产品创新。